Here is the design of a clinical trial:

Official Title: An Implementation Study of Suicide Risk Management Among Discharged Psychiatric Patients Based on Brief Contact Interventions and Sequential Multiple Assignment Randomized Trial

Included conditions:
- Suicide

Study Armgroups:
- {'label': 'Group 1a', 'type': 'EXPERIMENTAL', 'description': "After recruitment and baseline survey, participants will be randomized into Group 1 and Group 2. In Group 1, participants will receive brief contact intervention (BCI) monthly. If participants' suicide risk increased at 3 months after discharge, they will be re-randomized into Group 1a and Group 1b to receive BCIs weekly (Group 1a) and bi-weekly (Group 1b).", 'interventionNames': ['Other: Brief contact intervention']}
- {'label': 'Group 1b', 'type': 'EXPERIMENTAL', 'description': "After recruitment and baseline survey, participants will be randomized into Group 1 and Group 2. In Group 1, participants will receive brief contact intervention (BCI) monthly. If participants' suicide risk increased at 3 months after discharge, they will be re-randomized to receive BCIs weekly (Group 1a) and bi-weekly (Group 1b).", 'interventionNames': ['Other: Brief contact intervention']}
- {'label': 'Group 1c', 'type': 'EXPERIMENTAL', 'description': "After recruitment and baseline survey, participants will be randomized into Group 1 and Group 2. In Group 1, participants will receive brief contact intervention (BCI) monthly. If participants' suicide risk decreased or did not change, they will remain receiving BCIs monthly as Group 1c.", 'interventionNames': ['Other: Brief contact intervention']}
- {'label': 'Group 2a', 'type': 'EXPERIMENTAL', 'description': 'After recruitment and baseline survey, participants will be randomized into Group 1 and Group 2. In Group 2, participants will receive brief contact intervention (BCI) weekly. If the suicide risk increased or did not change, they will remain receiving BCIs weekly as Group 2a.', 'interventionNames': ['Other: Brief contact intervention']}
- {'label': 'Group 2b', 'type': 'EXPERIMENTAL', 'description': 'After recruitment and baseline survey, participants will be randomized into Group 1 and Group 2. In Group 2, participants will receive brief contact intervention (BCI) weekly. If the suicide risk decreased, they will be re-randomized to receive BCIs monthly (Group 2b) and bi-weekly (Group 2c).', 'interventionNames': ['Other: Brief contact intervention']}
- {'label': 'Group 2c', 'type': 'EXPERIMENTAL', 'description': 'After recruitment and baseline survey, participants will be randomized into Group 1 and Group 2. In Group 2, participants will receive brief contact intervention (BCI) weekly. If the suicide risk decreased, they will be re-randomized to receive BCIs monthly (Group 2b) and bi-weekly (Group 2c).', 'interventionNames': ['Other: Brief contact intervention']}

Interventions:
- {'type': 'OTHER', 'name': 'Brief contact intervention', 'description': "The BCI in this study is a series of structured messages, and messages will be delivered to participants by pushing feeds through WeChat and an iOS/Android application developed for this study. If participants did not use smartphones, messages will be delivered by mobile text messages or by phone calls. Though the final details are yet to be determined by the CBPR study, the investigators expect to structure messages into six components including introduction, greetings for previous complains, mental health promotion, encouragement, and coping strategies, remind of treatment and subsequent visit, and crisis intervention resource.\n\nNoted, the same messages will also be sent to patients' LHSs.", 'armGroupLabels': ['Group 1a', 'Group 1b', 'Group 1c', 'Group 2a', 'Group 2b', 'Group 2c']}

Primary Outcomes:
- {'measure': 'The trajectory of suicide ideation from baseline to three months after discharge', 'description': "This study will use the Beck Suicide Ideation Scale-Chinese Version (BSI-CV) to assess participants' suicide ideation. The BSI-CV includes 19 items, and each item scores from 0 to 2 with a total score ranging from 0 to 38, and a higher score indicates a higher level of suicide ideation. The total score's trajectory from baseline to three months after discharge will be recorded and compared.", 'timeFrame': 'It will be evaluated at three months after discharge.'}
- {'measure': 'The trajectory of suicide ideation from baseline to 12 months after discharge', 'description': "This study will use the Beck Suicide Ideation Scale-Chinese Version (BSI-CV) to assess participants' suicide ideation. The BSI-CV includes 19 items, and each item scores from 0 to 2 with a total score ranging from 0 to 38, and a higher score indicates a higher level of suicide ideation. The total score's trajectory from baseline to 12 months after discharge will be recorded and compared.", 'timeFrame': 'It will be evaluated at 12 months after discharge.'}

Please estimate the sample size based on the assumption: 
type I error α at 0.05, type II error β at 0.20, power (1-β) at 0.80, and a 20% increase in sample size to account for dropout
Sample size
            The sample size was calculated to estimate the primary effect between group 1 and group 2 in the trial.67 We set the rate of type I error Î± at 0.05, the rate of type II error Î² at 0.20, the power (1-Î²) at 0.80, the moderate effect size d at 0.35,68 and the sample size is 130 for each group, 260 in total; considering dropout, we will increase the sample size by 20%, and the final sample size is 312 participants. We will conduct two SMART trials in patients with psychotic symptoms and MDD separately, and the sample size for each trial is 312 (624 patients in total). We aim to recruit participants from 1 January 2022 until the sample size is reached.